Staphylococcus aureus is a common cause of surgical-site infections. Physicians report an increased proportion of these infections due to MRSA, a serious, potentially life-threatening infection that is becoming increasingly resistant to current treatments.
"Surgical site infections are a significant cause of death following surgery, and while vancomycin is a mainstay for treatment of these infections caused by MRSA, its decreasing effectiveness highlights the need for new antibiotics," said Samuel E. Wilson, MD, Professor of Surgery, University of California Irvine School of Medicine. "We are hopeful that telavancin will be a safe and useful treatment for serious and life-threatening complicated skin and skin structure infections."
Multiple Studies Support Telavancin
In addition to the analysis of a subset of patients with surgical site infections, 13 other telavancin abstracts were accepted at this year's ICAAC meeting. These data from multiple studies, taken in their entirety, provide insight into the potential benefits of telavancin. Abstracts included:
-- Comparative Use of Telavancin and Daptomycin Against MRSA in the
Neutropenic Murine Thigh Model
In this study, mice thigh tissue was injected with MRSA and dosed with
telavancin or daptomycin three or eight hours later. At three hours
following MRSA injection, reduction in bacteria concentrations were
comparable between the two treatments. However, at eight hours,
telavancin reduced bacteria concentrations to a greater degree than
|SOURCE Astellas Pharma US, Inc.|
Copyright©2007 PR Newswire.
All rights reserved